Time Course Distributions of Laboratory Indices: A Strategy for Evaluating Laboratory Data from Clinical Trials

Time Course Distributions of Laboratory Indices: A Strategy for Evaluating Laboratory Data from Clinical Trials

Conference: ICAAC

The traditional approach for assessing drug safety is to compute the baseline to end of treatment change in a laboratory measure. This strategy may miss important time-dependent value trends in patient...

Population Pharmacokinetics (PK) of Linezolid in Patients with Community-Acquired Pneumonia (CAP) and Skin and Soft Tissue (SST) Infections

Population Pharmacokinetics (PK) of Linezolid in Patients with Community-Acquired Pneumonia (CAP) and Skin and Soft Tissue (SST) Infections

Conference: ICAAC

A population PK analysis from 3 linezolid (LZD) trials was performed to estimate PK parameters in patients with CAP and SST infections, and evaluate patient covariate influence on LZD PK.

Characterization Of Oritavancin Pharmacokinetics (Pk) In Plasma And Blister Fluid In Normal Healthy Volunteers

Characterization Of Oritavancin Pharmacokinetics (Pk) In Plasma And Blister Fluid In Normal Healthy Volunteers

Conference: ICAAC

Oritavancin is a novel glycopeptide antibiotic currently being developed for the treatment of complicated skin/skin structure infections (cSSSI), including those caused by multi-drug resistant Gram-positive…

A strategy for Urinary Incotinence Management in the Nursing Home – A Mandated Outcome Measure

A strategy for Urinary Incotinence Management in the Nursing Home – A Mandated Outcome Measure

Conference: DIA

Urinary incontinence (UI) is prevalent in more than 50% of nursing home residents. It significantly affects the quality of a resident's life and is one of the most common complaints by family members.

Phase III Population Pharmacokinetics And Pharmacodynamics Of Azimilide

Phase III Population Pharmacokinetics And Pharmacodynamics Of Azimilide

Conference: AAPS

Azimilide (AZ) is a class III antiarrhythmic drug being developed for the treatment of symptomatic atrial fibrillation/flutter (AF/FL) and/or symptomatic paroxysmal supraventricular tachycardia…

The Development of a Population Pharmacokinetic (PK) Model for Linezolid

The Development of a Population Pharmacokinetic (PK) Model for Linezolid

Conference: ICAAC

Linezoid (lzd) is an oxazolidinone antibiotic under development for infection due to gram-positive bacteria. It is rapidly and extensively absorbed following oral administration and initial PK studies…

Benchmarking And Risk Adjustment Of Patient Outcomes Across Anesthesia Provider Teams

Benchmarking And Risk Adjustment Of Patient Outcomes Across Anesthesia Provider Teams

Conference: IARS

In our current health care climate, it is becoming more common to compare patient outcome benchmarks across institutions and across providers within an institution. The JCAHO is mandating hospitals to…

Contributing Factors To Serious Adverse Outcomes

Contributing Factors To Serious Adverse Outcomes

Conference: IARS

JCAHO is an accrediting body for hospitals in the United States. As part of the accreditation process, the JCAHO is initiating a new program called ORYX. The goal of the program is to integrate routinely…

Efficacy Of Bupropion Sr On Reducing Craving In Smoking Cessation

Efficacy Of Bupropion Sr On Reducing Craving In Smoking Cessation

Conference: CINP Congress

Bupropion HCl sustained release (Bup SR, ZybanTM) is the first non-nicotine treatment proven to be safe and effective for smoking cessation. Clinical studies have demonstrated that when used in…

Implementation of concentration dependent “first-pass” models using NONMEM

Implementation of concentration dependent “first-pass” models using NONMEM

Authors: Phillips L, Cox SR
Conference: AAPS

The development of drugs extensively metabolized by the P450 enzyme system may require the need to model concentration dependent 'first-pass' effects. This simulation study, performed using NONMEM…